文献速递血液透析通路

血液透析可靠流出道移植物感染的发生率与危险因素

Incidence and risk factors for Hemodialysis Reliable Outflow bypass graft infection.
PubMed 文献 · J Vasc Surg · 2025-08-21

单中心回顾性研究纳入2014至2023年232例首次HeRO移植物植入患者,中位随访18.5个月。57例(24.6%)发生移植物感染,估计1年和3年感染发生率分别为14.9%±2.6%和34.2%±4.3%。

要点

  • HeRO移植物感染率高,1年14.9%,3年达34.2%。
  • 女性是HeRO移植物感染的独立危险因素。
  • 感染后二次通畅率显著降低,中位生存仅0.95年。

核心结论

  • HeRO移植物感染发生率高,且术后数年持续存在风险。
  • 女性是HeRO移植物感染的独立危险因素。

研究设计与样本

  • 单中心回顾性队列研究,纳入2014至2023年232例首次HeRO移植物手术患者。
  • 中位随访18.5个月,采用Kaplan-Meier、单因素和多因素分析。

主要发现

  • 57例(24.6%)诊断为HeRO移植物感染。
  • 估计1年和3年感染发生率分别为14.9%±2.6%和34.2%±4.3%。
  • 感染诊断后中位生存0.95年(IQR 0.50-2.18年)。

关键数值与推荐

  • 从手术至感染的中位间隔0.93年(IQR 0.16-1.88年)。
  • 94.7%(54例)感染患者接受完整移植物切除联合静脉抗生素治疗。
  • 最常见病原体为金黄色葡萄球菌(21.1%)、混合菌(19.3%)和表皮葡萄球菌(14.0%)。

临床怎么用

  • 植入HeRO移植物前应告知患者感染风险及后果。
  • 女性患者需加强感染监测与预防。
  • 感染后常需完整移植物切除并静脉抗生素,移除后使用非隧道导管直至感染控制。

局限性

  • 单中心回顾性研究,可能存在选择偏倚和信息偏倚。
  • 仅纳入首次手术,未纳入后续手术。
  • 随访时间有限,中位随访18.5个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemodialysis Reliable Outflow (HeRO) graft implantation is performed as a last resort option for hemodialysis access in patients limited by central venous stenosis or occlusion. In this single-center series, we examined the incidence, risk factors, and long-term outcomes of patients with a HeRO graft infection. METHODS: Institutional medical records were retrospectively reviewed for all HeRO graft procedures performed from 2014 to 2023. Only index procedures were included in this analysis. The primary outcome of interest was HeRO graft infection. Data were analyzed using Kaplan-Meier, univariable, and multivariate analyses. RESULTS: Over the 10-year study period, 232 patients underwent index HeRO graft surgery with a median follow-up period of 18.5 months. A total of 57 patients (24.6%) were diagnosed with a HeRO graft infection. The estimated 1- and 3-year incidences of graft infection were 14.9% ± 2.6% and 34.2 ± 4.3%, respectively. The median interval from operation to infection was 0.93 years (interquartile range, 0.16-1.88 years). Patients with graft infection were more frequently female (63.2% vs 46.3%; P = .03). Most patients were treated with complete graft resection and intravenous antibiotics (n = 54 [94.7%]). After the infected graft is removed, a nontunneled catheter is used until the infection has been adequately treated. The most common pathogens were Staphylococcus aureus (n = 12 [21.1%]), polymicrobial cultures (n = 11 [19.3%]), and Staphylococcus epidermidis (n = 8 [14.0%]). Primary patency rates were similar between the groups (1 year, 23.8 ± 5.7% vs 37.1 ± 4.1%; log-rank P = .15). However, secondary patency rates were significantly lower among patients with graft infection at 1 year (47.0 ± 6.7% vs 78.6 ± 3.7%) and 3 years (13.8 ± 4.7% vs 59.1 ± 5.4%) (log-rank P < .0001). The median survival after diagnosis of graft infection was 0.95 years (interquartile range, 0.50-2.18 years). On multivariate analysis, only female sex (hazard ratio, 1.89; 95% CI, 1.08-3.31; P = .026) was independently associated with HeRO graft infection. CONCLUSIONS: The incidence of HeRO graft infection is high and persists for years after the index operation. Patients undergoing HeRO graft implantation should be counseled on the risks and consequences of this complication.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kim Y, Cui CL, Chun TT, et al. Incidence and risk factors for Hemodialysis Reliable Outflow bypass graft infection. J Vasc Surg. 2025. PMID: 40849008. doi:10.1016/j.jvs.2025.08.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。